Board of Directors

Theo . H . Walthie (Business consultant and strategic advisor)
Chairman of the Board

Theo Walthie holds a degree in Chemical Engineering from Technical University of Delft, The Netherlands. He is an experienced senior executive who had assumed global responsibilities in the leading global petro-chemical company Dow Chemical. Theo Walthie joined Dow Europe in 1970 where he started his career in Sales Technical Service, Marketing and Manufacturing in both Switzerland and The Netherlands. In 1974, he joined the Dow Europe Purchasing group in Rotterdam, the Netherlands, followed by becoming business manager for Dow Chemical Iberica in 1978, where he was instrumental for significantly growing Dow in this region. In 1982, he became responsible for Dow Europe’s Hydrocarbon Feedstock Supplies operating out of Switzerland and in 1986 Business Vice President for Dow's Hydrocarbons Group and later Vice President Polyurethanes. He took on management responsibility for Dow's Thermosets Business Group by merging Polyurethanes with Epoxy Resins and Intermediates in 1991 and the Dow Europe Automotive group in 1992.

In 1995 Theo Walthie was named Global Vice President and subsequent Business Group President for the Hydrocarbons & Energy Business of Dow worldwide until his retirement in 2007.
During his tenure in DOW  He assumed responsibilities as president-elect and board member in various industry organizations (e.g. among others, the Association of Petro-Chemical Producers Europe, APPE, the European Petro-Chemical Association, EPCA, the European Chemical Industry Council, CEFIC, An High Level Group of the EU Commission ). After his retirement he has also been advisor to the CEO/Chairman of the Dow Chemical Co.,The Accenture Energy Advisory Board, the Kuwait Petroleum Co, and Chairman of the Energy Transition Board for the Dutch Government. Since 2010, Theo Walthie also serves as a Board member of German DAX-company, Lanxess, and is involved as strategic advisor in life science companies.

 

 

Detlev Mennerich, PhD (Senior Investment Manager at Boehringer Ingelheim Venture Fund)

Detlev Mennerich is Senior Investment Manager at the Boehringer Ingelheim Venture Fund. Over the last five years, he led several investments of the therapeutics fund. He served as board member of ViraTherapeutics GmbH in Innsbruck (Austria), which was acquired by Boehringer Ingelheim in September 2018. Currently, Detlev serves at the Board of Imcheck Therapeutics in Marseilles (France), HepaRegenix in Tübingen (Germany), Topas Therapeutics in Hamburg (Germany), as well as of NBE Therapeutics in Basel (Switzerland). In addition, he is member of the Supervisory and the Scientific Advisory Board of Advent France Biotechnology, a French Seed Investment Fund based in Paris (France). Detlev Mennerich studied Chemistry in Braunschweig (Germany) and Bordeaux (France) and holds a PhD in Cell & Molecular Biology. In 2001, he started his industrial career at metaGen Pharmaceuticals and Schering AG in Berlin (Germany) as a Scientist in Oncogenomics focusing on target validation and biomarker research. In 2005, he joined Boehringer Ingelheim in Biberach an der Riss (Germany), where he held several positions in Research: he started as Laboratory Head in Genomics for new drug concept nominations. In 2009, Detlev moved to Ridgefield, CT (USA) as Project Leader for an anti-inflammatory antibody project. In 2011, he returned to Biberach heading the Target Validation Technologies Group supporting all diseases areas in new drug concept creation. Beginning of 2014, he joined the Boehringer Ingelheim Venture Fund investing in clinical translation of pioneering therapeutic approaches, i.e. in the field of immuno-oncology, immuno-tolerization and regenerative concepts.

 

Jens Hennecke, PhD (Representative of PPF Group)

Jens Hennecke is Chief Business Officer of SOTIO a.s. since March 2015. He is responsible for business strategy as well as for licensing, M&A and investments at Sotio, and as such, for PPF Group’s investment and partnering activities in the biotechnology sector. Jens is a molecular biologist by training and has more than 15 years of business and deal-making track record in the biopharmaceutical industry. Before joining SOTIO, he had his own business consulting firm and has been serving as an advisor for business and corporate development for various European biotech companies. Until 2012, Jens was Senior Vice President for Business Development and a member of the executive management team of Nasdaq-listed Micromet, Inc.. At Micromet, he was responsible for business development, alliance management, intellectual property and other operational functions. During his 12 years tenure at Micromet, Jens closed corporate deals and managed the alliances with multiple large pharma companies on Micromet’s T cell engager BiTE platform and products, and has been instrumental in the $1.2 billion acquisition of Micromet by Amgen in 2012. He received a diploma in biology from the University of Göttingen and completed his Ph.D. thesis at the ETH Zurich. He also carried out post-doctoral research at Harvard University. Jens currently also serves on the supervisory board of Cytune Pharma.

 

Hans-Peter Gerber, PhD

Since April 2017 Hans-Peter Gerber serves as an independent, non-executive Director on the Board at NBE Therapeutics. Hans-Peter has more than 20 years of research and development experience in the field of Biotherapeutics in Oncology, including antibody-drug conjugates (ADC), redirected T-cell targeting compounds and nanoparticles. Most recently he was CSO of Pfizer’s Bioconjugates division where he was leading Pfizer’ s efforts in the ADC and bispecific, redirected T-cell targeting field. He also held senior leadership positions at Seattle Genetics and Genentech. Hans-Peter is currently CSO and President at the immune-oncology company Maverick Therapeutics, Inc.

Hans-Peter holds a PhD in Molecular Biology from the University of Zurich, Switzerland and he is an internationally recognized leader in Oncology drug research and development with a strong record of accomplishments in the field of antibody-based targeted therapeutics. His work led to over ten IND filings for ADCs and bi-specifics, and contributions to BLA submissions of therapeutic antibodies and two ADCs in Oncology. He is an author on over 90 peer-reviewed published papers and inventor on 15 patents in the field of oncology.

 

Nicole Onetto, MD

Dr. Nicole Onetto has joined NBE-Therapeutics' Board of Directors in November 2017 as an independent Board member. Nicole is a medical doctor with over 20 years industry experience in clinical development of targeted cancer therapeutics. Previously, from 2009 to 2016, she was Deputy Director & Chief Scientific Officer at the Ontario Institute for Cancer Research (OICR) in Toronto, Canada.

From 2005-2009 she was Senior Vice President and Chief Medical Officer at ZymoGenetics Inc., a Seattle-based Biotechnology company specializing in the development of protein therapeutics. Between 2002 and 2005, she served as Executive Vice President-Oncology and Chief Medical Officer at OSI Pharmaceuticals, Inc., a New York based biopharmaceutical company developing targeted cancer therapies. Her career in the pharmaceutical industry also included senior management positions at Bristol-Myers Squibb, Nexstar Pharmaceuticals, Immunex R&D Corporation and Hoechst Canada, Inc.

Nicole is currently also serving on the Boards of Sierra Oncology, a Vancouver-based Oncology Hematology company, and of Basilea Pharmaceuticals, a Basel-Switzerland-based clinical-stage biopharmaceutical company active in the development of anti-infective and cancer drugs. Previously, Nicole also served for eleven years on the Board of Waltham/Boston-area-based ImmunoGen Inc., which is one of the pioneers in the ADC development field. Nicole obtained her MD from the University of Paris and holds a Master of Pharmacology from the University of Montréal.

 

Ulf Grawunder,PhD (founder and CEO)

Ulf Grawunder is an experienced Swiss Life-Science entrepreneur with over 10 years experience in the therapeutic antibody development industry. With NBE-Therapeutics, he has recently founded his second Swiss Biotech company and is leading NBE-Therapeutics as its CEO since June 2012. 
Ulf Grawunder has invented two new patent-pending technologies at NBE-Therapeutics that allow the company to develop most innovative antibody-based drugs, including next-generation antibody drug conjugates (ADCs) for the therapy of cancer. Before that, Ulf Grawunder co-founded the Swiss Biotech company 4-Antibody, recently sold to U.S.-based Agenus (AGEN), where since 2004 he served as founding CEO and after 2006 assumed the role of CSO. During his tenure at 4-Antibody, Ulf Grawunder raised about CHF 50 million capital for the company, secured two pharma/biotech collaborations with Boehringer Ingelheim, Germany, and Human Genome Sciences, U.S.A. and grew the company to 50 employees.

Ulf Grawunder is serving on various Boards of non-profit and for-profit life-science organizations and is vice-president and Board member of the Swiss Biotech Association. Ulf Grawunder holds a PhD in Cell Biology from the University of Basel, for work on early B cell development performed at the Basel Institute for Immunology. In addition, Ulf Grawunder holds a Diploma in Technology Entrepreneurship from the Entrepreneur and Business School in St. Gallen, Switzerland (HSG=Hochschule St. Gallen).